Biotech & Pharma

Novartis, UNP, Launch Up-to-$1.8B+ Macrocyclic Peptide Partnership

23 sec read15 views0 listens

Novartis and Unnatural Products (UNP) have launched a partnership to develop next-generation cardiovascular disease treatments using UNP's AI-guided macrocyclic peptide platform, potentially worth over $1.8 billion for UNP. This collaboration highlights the potential of macrocyclic peptides in targeting previously undruggable biological targets, offering new avenues in drug discovery and development.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

CybersecurityMay 1027 sec read

French evacuee from hantavirus-hit ship has 'symptoms': French PM

One of five French passengers repatriated from a cruise ship affected by a hantavirus outbreak is showing symptoms and has been placed in isolation. This development underscores the ongoing health risk associated with the virus, which can spread amon...

Ali Nemati

AI & Machine LearningMay 925 sec read

WHO says hantavirus is 'not another COVID-19' and that the public health risk 'remains low'

The World Health Organization's director-general stated that the current hantavirus outbreak, linked to three deaths on a cruise ship, is not another COVID-19 and poses a low public health risk. This assurance is crucial for calming fears among Tener...

Ali Nemati

CybersecurityMay 924 sec read

Canary Islands brace for arrival of hantavirus-hit cruise ship

A cruise ship carrying nearly 150 passengers infected with a deadly strain of hantavirus is set to arrive in the Canary Islands, prompting evacuations and health screenings. This development raises concerns among residents and authorities due to the ...

Ali Nemati